Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species
about
In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazoleEpidemiology of invasive candidiasis: a persistent public health problemCandida albicans SET1 encodes a histone 3 lysine 4 methyltransferase that contributes to the pathogenesis of invasive candidiasis.Caspofungin susceptibility testing of isolates from patients with esophageal candidiasis or invasive candidiasis: relationship of MIC to treatment outcomeSpecific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates.Use of fluorescent probes to determine MICs of amphotericin B and caspofungin against Candida spp. and Aspergillus spp.Canadian clinical practice guidelines for invasive candidiasis in adults.Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy.Candida parapsilosis, an emerging fungal pathogenMicafungin in the treatment of invasive candidiasis and invasive aspergillosisGlobal surveillance of in vitro activity of micafungin against Candida: a comparison with caspofungin by CLSI-recommended methods.Antifungal effects on metabolite profiles of medically important yeast species measured by nuclear magnetic resonance spectroscopy.Concentration-dependent effects of caspofungin on the metabolic activity of Aspergillus species.Comparative evaluation of Etest and sensititre yeastone panels against the Clinical and Laboratory Standards Institute M27-A2 reference broth microdilution method for testing Candida susceptibility to seven antifungal agentsKodamaea ohmeri isolates from patients in a university hospital: identification, antifungal susceptibility, and pulsed-field gel electrophoresis analysis.Further standardization of broth microdilution methodology for in vitro susceptibility testing of caspofungin against Candida species by use of an international collection of more than 3,000 clinical isolates.Species-specific differences in the susceptibilities of biofilms formed by Candida bloodstream isolates to echinocandin antifungals.Role for cell density in antifungal drug resistance in Candida albicans biofilmsQuality control and reference guidelines for CLSI broth microdilution method (M38-A document) for susceptibility testing of anidulafungin against molds.The Ssk1p response regulator and Chk1p histidine kinase mutants of Candida albicans are hypersensitive to fluconazole and voriconazole.Echinocandins: role in antifungal therapy, 2005.Caspofungin: an overview.Effect of caspofungin on metabolite profiles of Aspergillus species determined by nuclear magnetic resonance spectroscopyComparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidiaLodderomyces elongisporus masquerading as Candida parapsilosis as a cause of bloodstream infectionsComparative in vitro activities of caspofungin and micafungin, determined using the method of the European Committee on Antimicrobial Susceptibility Testing, against yeast isolates obtained in France in 2005-2006Posaconazole activity against Candida glabrata after exposure to caspofungin or amphotericin B.Echinocandin antifungals: review and update.Emerging echinocandins for treatment of invasive fungal infections.The echinocandins.Detection of caspofungin resistance in Candida spp. by Etest.The pharmacology and clinical use of caspofungin.Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints.Micafungin activity against Candida albicans with diverse azole resistance phenotypes.Mutations in the fks1 gene in Candida albicans, C. tropicalis, and C. krusei correlate with elevated caspofungin MICs uncovered in AM3 medium using the method of the European Committee on Antibiotic Susceptibility Testing.Characterization of caspofungin susceptibilities by broth and agar in Candida albicans clinical isolates with characterized mechanisms of azole resistanceEpidemiology and antifungal susceptibility of bloodstream Candida isolates in Quebec: Report on 453 cases between 2003 and 2005.Caspofungin MICs correlate with treatment outcomes among patients with Candida glabrata invasive candidiasis and prior echinocandin exposureAntimicrobial resistance: resistance to antifungal agents: mechanisms and clinical impact.Activity profile in vitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds.
P2860
Q24538858-C76FAB28-D2AE-46D2-889A-F51A6926249CQ29616758-6D6DB963-A8A3-448A-8958-71D6BC0FF166Q33240623-569F156F-951D-40C6-A6AF-3B4D8249D70DQ33935389-702FA843-8F9F-4959-8407-DD91884F8C97Q33938068-986BA1CC-CDAB-40AD-9CAD-F9C655B06889Q34041801-E79712E8-EA6A-47C3-9938-EEEFEC25C6C5Q34237335-2C78FEFF-A852-4126-B8A3-1F87754D87F9Q34721774-2276D399-FDD6-406B-A3BF-C4C059FACBA6Q34852747-0D760866-5521-4067-AD65-081B8C496907Q35026516-A0459A41-1DEA-4CD5-8BE5-22F4AFD18480Q35073614-F0DE21A1-C073-4FB1-9400-878B506549B6Q35215404-377C5DBD-CB74-4854-92BB-0CFC36F37ED7Q35647724-EF38BFD2-581F-46C0-BA39-8E0E443750E2Q35690629-5F4C356A-2EB0-4935-BDBC-C26B5657CACAQ35690723-77EA41DA-7D04-4888-8964-16713AB3F71FQ35718542-9926445F-0D16-41E8-B52F-74C41C6386DFQ35758901-7C43F198-545C-4BAC-9312-945D921C00AFQ35878982-EB7E8DC9-EAB5-4F20-9A43-DDD384AF951BQ35913719-079CF5AD-554F-4105-B0E9-E5664D938B44Q36095050-9CA1B2EB-8593-4F92-9BC4-427511FDAF40Q36222035-7A659F10-246D-4608-9A15-B1D6E918448DQ36278031-23E92AF8-9E27-482C-AAA2-15F856DE06EEQ36295480-45D76245-AA57-49CE-A230-FCC6BF6B91EEQ36422666-E5A22F96-F875-41F1-AE88-4B3863DD43E1Q36423792-6BBE2F5A-658A-4AD2-AAA3-65A24837632FQ36424929-04C8F66B-8840-4DD1-BA4B-97C06F3BD082Q36424973-381FD4AA-99D5-4EAE-877C-81EA35806135Q36441524-928BDF70-0727-4052-BD2F-03E73755DC6DQ36458402-77004A9A-A73A-4819-8719-9782C841EA1CQ36742397-B05CB36D-1D4B-4E23-A852-FD3600EBFF7FQ36747567-903E6D55-1EC2-425C-9801-310EB91ACA6CQ36788428-5662BCE0-12A9-4159-8638-EF2D09623D02Q36845482-BC9C2885-990C-4029-96F1-AFFD5CFA4253Q36867925-D25C857A-CD97-4B8A-B84B-67C5C0000BCAQ36870777-764D8775-3EDE-4434-97FE-59CB49ECA789Q36925967-89578729-0D24-46E1-A083-1120113256E2Q37029222-D5264AB4-3827-4E67-984A-5181E7F25A74Q37036603-301A478A-2C69-4EA5-B0C0-54C2ADD7EE02Q37048679-17A283B6-E0E4-4CA9-8F48-0171AF838322Q37190686-8EC40E06-30B2-4328-923E-9317BDDBE92F
P2860
Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 2004
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Interlaboratory comparison of ...... andida and Aspergillus species
@en
Interlaboratory comparison of ...... ndida and Aspergillus species.
@nl
type
label
Interlaboratory comparison of ...... andida and Aspergillus species
@en
Interlaboratory comparison of ...... ndida and Aspergillus species.
@nl
prefLabel
Interlaboratory comparison of ...... andida and Aspergillus species
@en
Interlaboratory comparison of ...... ndida and Aspergillus species.
@nl
P2093
P2860
P50
P1476
Interlaboratory comparison of ...... andida and Aspergillus species
@en
P2093
Amanda Davidson
Annette W Fothergill
Christian Durussel
Christine Shields
David Ellis
David W Warnock
Deanna A Sutton
Elyse Foraker
Emilia Cantón
Frank C Odds
P2860
P304
P356
10.1128/JCM.42.8.3475-3482.2004
P407
P577
2004-08-01T00:00:00Z